Biocryst Pharmaceuticals Stock News

BioCryst (BCRX) starts patient enrollment in the pivotal REDEEM-2 study evaluating BCX9930 for treating patients with paroxysmal nocturnal hemoglobinuria.

Bionano Genomics, BioCryst Pharmaceuticals, and NRx Pharmaceuticals all have the potential to make their early shareholders rich.

RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first patient in the REDEEM-2 pivotal trial with i

RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the enrollment of the first patient in the REDEEM-2 pivotal trial with its oral Factor D inhibitor, BCX9930, in patients with paroxysmal nocturnal hemoglobinuria (PNH).

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)s share price was up 3.4% during mid-day trading on Friday . The stock traded as high as $13.00 and last traded at $12.93. Approximately 10,905 shares traded hands during mid-day trading, a decline of 100% from the average daily volume of 3,455,892 shares. The stock had previously closed at $12.50. Several []

Related Stocks: BCRX ,

BioCryst Pharmaceuticals (NASDAQ:BCRX) and Adaptimmune Therapeutics (NASDAQ:ADAP) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, profitability, earnings and risk. Risk & Volatility BioCryst Pharmaceuticals has a beta of 2.51, suggesting that its share price is []

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) CFO Anthony Doyle purchased 35,258 shares of the companys stock in a transaction on Tuesday, November 23rd. The stock was acquired at an average price of $12.48 per share, for a total transaction of $440,019.84. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is []

Royalty Pharma plc (NASDAQ: RPRX ) and OMERS Capital Markets have announced transactions worth $350 million in new funding in BioCryst Pharmaceuticals Inc (NASDAQ: BCRX ). The largest buyer of pharmaceutical royalties globally, Royalty Pharma has purchased royalties for $150 million upfront on combined annual net sales of BCX9930 and another earlier stage Factor D inhibitor. Royalty Pharma also purchased royalties, declining Full story available on Benzinga.com

NEW YORK , Nov. 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for INVZ, AVYA, BCRX, LAC, and FCEL. Full story available on Benzinga.com

NEW YORK and RESEARCH TRIANGLE PARK, N.C., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX), BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) and OMERS Capital Markets (OMERS) today announced transactions totaling $350 million in new funding for BioCryst, with all funds immediately available at closing.

—Provides funding for BCX9930/oral Factor D program across multiple indications—

Royalty Pharma plc (NASDAQ: RPRX) and OMERS Capital Markets have announced transactions worth $350 million in new funding in BioCryst Pharmaceuticals Inc (NASDAQ: BCRX). The largest buyer of ph

The small molecule sterile injectable drugs market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 7.2% in the forecast period